Nilotinib treatment of patients affected by chronic graft-versus-host disease reduces collagen production and skin fibrosis by down-modulating the TGF- β and p-SMAD pathway.

Chronic Graft-Versus-Host Disease (cGVHD), a major complication of allogeneic stem cell transplantation (allo-HCT), is an immune-mediated disease resulting from a complex interaction between donor and recipient adaptive immunity, leading to reduced patient-reported quality of life and non-relapse mortality1,2.

Source: Biology of Blood and Marrow Transplantation - January 28, 2020 Category: Hematology Authors: Marinelli Busilacchi Elena, Costantini Andrea, Mancini Giorgia, Tossetta Giovanni, Olivieri Jacopo, Poloni Antonella, Viola Nadia, Butini Luca, Campanati Anna, Goteri Gaia, Marzioni Daniela, Attilio Olivieri Source Type: research